These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 34119742)
61. A radiopharmaceutical [ Tang Y; Hu Y; Liu W; Chen L; Zhao Y; Ma H; Yang J; Yang Y; Liao J; Cai J; Chen Y; Liu N Nucl Med Biol; 2019 Mar; 70():23-31. PubMed ID: 30826708 [TBL] [Abstract][Full Text] [Related]
62. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy. Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH Front Immunol; 2021; 12():654463. PubMed ID: 34054817 [TBL] [Abstract][Full Text] [Related]
63. Detecting TRA-1-60 in Cancer via a Novel Zr-89 Labeled ImmunoPET Imaging Agent. White JM; Kuda-Wedagedara AN; Wicker MN; Spratt DE; Schopperle WM; Heath E; Viola NT Mol Pharm; 2020 Apr; 17(4):1139-1147. PubMed ID: 32069422 [TBL] [Abstract][Full Text] [Related]
64. Positron Emission Tomography Imaging of Platelet-Derived Growth Factor Receptor β in Colorectal Tumor Xenograft Using Zirconium-89 Labeled Dimeric Affibody Molecule. Cai H; Shi Q; Tang Y; Chen L; Chen Y; Tao Z; Yang H; Xie F; Wu X; Liu N; Yang Y; Wu H; Tian R; Lu X; Li L Mol Pharm; 2019 May; 16(5):1950-1957. PubMed ID: 30986347 [TBL] [Abstract][Full Text] [Related]
65. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between Bailly C; Gouard S; Guérard F; Chalopin B; Carlier T; Faivre-Chauvet A; Remaud-Le Saëc P; Bourgeois M; Chouin N; Rbah-Vidal L; Tripier R; Haddad F; Kraeber-Bodéré F; Bodet-Milin C; Chérel M Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137758 [TBL] [Abstract][Full Text] [Related]
67. The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and Vivier D; Fung K; Rodriguez C; Adumeau P; Ulaner GA; Lewis JS; Sharma SK; Zeglis BM Theranostics; 2020; 10(4):1746-1757. PubMed ID: 32042334 [No Abstract] [Full Text] [Related]
68. Preclinical Pharmacokinetics and Dosimetry of an Krache A; Fontan C; Pestourie C; Bardiès M; Bouvet Y; Payoux P; Chatelut E; White-Koning M; Salabert AS Front Med (Lausanne); 2021; 8():741855. PubMed ID: 35174180 [TBL] [Abstract][Full Text] [Related]
69. Evaluation of Anti-LGR5 Antibodies by ImmunoPET for Imaging Colorectal Tumors and Development of Antibody-Drug Conjugates. Azhdarinia A; Voss J; Ghosh SC; Simien JA; Hernandez Vargas S; Cui J; Yu WA; Liu Q; Carmon KS Mol Pharm; 2018 Jun; 15(6):2448-2454. PubMed ID: 29718672 [TBL] [Abstract][Full Text] [Related]
70. A novel [ Puyalto A; Rodríguez-Remírez M; López I; Iribarren F; Simón JA; Ecay M; Collantes M; Vilalta-Lacarra A; Francisco-Cruz A; Solórzano JL; Sandiego S; Peñuelas I; Calvo A; Ajona D; Gil-Bazo I Front Immunol; 2023; 14():1272570. PubMed ID: 37841258 [TBL] [Abstract][Full Text] [Related]
71. Evaluating the immunologically "cold" tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4 + and CD8 + T cells in breast cancer mouse models. Lu Y; Houson HA; Gallegos CA; Mascioni A; Jia F; Aivazian A; Song PN; Lynch SE; Napier TS; Mansur A; Larimer BM; Lapi SE; Hanker AB; Sorace AG Breast Cancer Res; 2024 Jun; 26(1):104. PubMed ID: 38918836 [TBL] [Abstract][Full Text] [Related]
72. In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1. Rubins DJ; Meng X; McQuade P; Klimas M; Getty K; Lin SA; Connolly BM; O'Malley SS; Haley H; Purcell M; Gantert L; Holahan M; Lindgren J; Eklund P; Ekblad C; Frejd FY; Hostetler ED; González Trotter DE; Evelhoch JL Mol Imaging Biol; 2021 Apr; 23(2):241-249. PubMed ID: 33098025 [TBL] [Abstract][Full Text] [Related]
73. PD-L1 ImmunoPET on the basis of Avidin/Biotin pre-targeted cancer imaging. Guo Z; Zhu L; Xu W; Luo X; Chen H; Li X; Zuo C Biochem Biophys Res Commun; 2023 Sep; 673():23-28. PubMed ID: 37354656 [TBL] [Abstract][Full Text] [Related]
74. First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET. Pouw JEE; Hashemi SMS; Huisman MC; Wijngaarden JE; Slebe M; Oprea-Lager DE; Zwezerijnen GJC; Vugts D; Ulas EB; de Gruijl TD; Radonic T; Senan S; Menke-van der Houven van Oordt CW; Bahce I J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38302416 [TBL] [Abstract][Full Text] [Related]
76. Interferon gamma immunoPET imaging to evaluate response to immune checkpoint inhibitors. Hackett JB; Ramos N; Barr S; Bross M; Viola NT; Gibson HM Front Oncol; 2023; 13():1285117. PubMed ID: 38130991 [TBL] [Abstract][Full Text] [Related]
77. Development of [ Ghai A; Zheleznyak A; Mixdorf M; O'Neal J; Ritchey J; Rettig M; DiPersio J; Shokeen M; Achilefu S Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1302-1311. PubMed ID: 33179150 [TBL] [Abstract][Full Text] [Related]
78. Radioimmunoimaging and targeting treatment in an immunocompetent murine model of triple-negative breast cancer using radiolabeled anti-programmed death-ligand 1 monoclonal antibody. Pang X; Liu M; Wang R; Liao X; Yan P; Zhang C J Labelled Comp Radiopharm; 2018 Sep; 61(11):826-836. PubMed ID: 29923634 [TBL] [Abstract][Full Text] [Related]
79. Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer. Wescott EC; Sun X; Gonzalez-Ericsson P; Hanna A; Taylor BC; Sanchez V; Bronzini J; Opalenik SR; Sanders ME; Wulfkuhle J; Gallagher RI; Gomez H; Isaacs C; Bharti V; Wilson JT; Ballinger TJ; Santa-Maria CA; Shah PD; Dees EC; Lehmann BD; Abramson VG; Hirst GL; Brown Swigart L; van ˈt Veer LJ; Esserman LJ; Petricoin EF; Pietenpol JA; Balko JM Cancer Res Commun; 2024 Apr; 4(4):1120-1134. PubMed ID: 38687247 [TBL] [Abstract][Full Text] [Related]
80. CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of Farwell MD; Gamache RF; Babazada H; Hellmann MD; Harding JJ; Korn R; Mascioni A; Le W; Wilson I; Gordon MS; Wu AM; Ulaner GA; Wolchok JD; Postow MA; Pandit-Taskar N J Nucl Med; 2022 May; 63(5):720-726. PubMed ID: 34413145 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]